Warhound has raised $200 million, reaching a $1.2 billion valuation to engineer military working dogs. The startup plans to reduce the U.S. military’s reliance on foreign canine imports by improving dog health and performance through gene-editing and sensor technology. The company expects the first cohort of these enhanced animals to arrive by early 2026.
Warhound, a new defense-focused startup, has emerged from stealth mode with a significant $200 million funding round. The venture, which has now achieved a $1.2 billion valuation, aims to transform how the U.S. military and law enforcement agencies procure and utilize working dogs. The company is backed by prominent investors including In-Q-Tel, Sequoia, and 8VC. Founded by Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril Industries, the company is positioning itself at the intersection of biotechnology and defense hardware.
Addressing the Supply Chain Gap
A core objective for Warhound is to solve the shortage of high-quality working dogs within the U.S. defense sector. Currently, more than 80% of military working dogs are sourced from Europe, a dependence that creates logistical and supply challenges. Furthermore, internal industry data suggests that less than half of these imported animals consistently meet the stringent health and performance standards required for modern mission profiles. By domesticating this supply chain, Warhound aims to ensure a more reliable and capable fleet of working animals.
Integrating Genetics and Tactical Tech
The company plans to use proprietary gene-editing techniques to address common genetic weaknesses found in traditional breeds like the German Shepherd and the Belgian Malinois. By banking specific cell lines, Warhound intends to eliminate hereditary health conditions, such as hip dysplasia and muscle atrophy. Beyond biological health, the company is looking to enhance physical and sensory capabilities. This biological foundation is paired with tactical hardware and software from Anduril Industries. The dogs will be equipped with sensor vests, which are designed to provide their human handlers with real-time data regarding the animal's physical state and situational awareness during operations.
Operational Timeline and Oversight
Cloning and biological development operations are being handled by Viagen, a subsidiary of Colossal Biosciences. The company has stated that the first cohort of these genetically enhanced animals is expected to be born by early 2026, with plans for field deployment in the defense and emergency response sectors to follow.
Because the use of gene-edited animals in public service involves complex ethical considerations, Warhound has stated it is operating under the guidance of the American Humane Society. This involvement is intended to ensure that training protocols are rigorous and that the long-term welfare of the animals is protected, including through formal retirement and reunification programs. For investors and the defense sector, the success of this project will depend on the company's ability to successfully execute its gene-editing roadmap, meet military procurement requirements, and navigate the ethical oversight necessary for such a high-stakes deployment.